[
  {
    "ts": null,
    "headline": "Are You a Value Investor? This 1 Stock Could Be the Perfect Pick",
    "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
    "url": "https://finnhub.io/api/news?id=b93460aa25c65512256862365df5012dbf2756a777acf297b5ae828005beb7af",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761658803,
      "headline": "Are You a Value Investor? This 1 Stock Could Be the Perfect Pick",
      "id": 137243991,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "COR",
      "source": "Yahoo",
      "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
      "url": "https://finnhub.io/api/news?id=b93460aa25c65512256862365df5012dbf2756a777acf297b5ae828005beb7af"
    }
  },
  {
    "ts": null,
    "headline": "Baxter Q3 Preview: Can Core Segments Deliver Another Solid Quarter?",
    "summary": "Baxter's Q3 results are expected to show steady revenue growth led by Advanced Surgery and Drug Compounding, though IV fluid and anesthesia softness may weigh on EPS.",
    "url": "https://finnhub.io/api/news?id=006965ff5fdd985b8ad03a6320026a3af6de0ab707c616354987a6c27f96c3d9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761657360,
      "headline": "Baxter Q3 Preview: Can Core Segments Deliver Another Solid Quarter?",
      "id": 137238357,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "COR",
      "source": "Yahoo",
      "summary": "Baxter's Q3 results are expected to show steady revenue growth led by Advanced Surgery and Drug Compounding, though IV fluid and anesthesia softness may weigh on EPS.",
      "url": "https://finnhub.io/api/news?id=006965ff5fdd985b8ad03a6320026a3af6de0ab707c616354987a6c27f96c3d9"
    }
  },
  {
    "ts": null,
    "headline": "United State Cell and Gene Therapy Third-Party Logistics Market Analysis Report 2025-2033: Expansion Fueled by Rising R&D Expenditure, Regulatory Complexity, & Strong Demand from Major Biopharma Hubs",
    "summary": "The U.S. Cell and Gene Therapy Third-Party Logistics (3PL) Market is anticipated to surge from US$ 2.61 billion in 2024 to US$ 5.88 billion by 2033, maintaining a CAGR of 9.46% from 2025 to 2033. Key growth drivers include increased therapy adoption, specialized logistics needs, and expanding biopharmaceutical collaborations. Regulatory demands, cold chain technology adoption, and challenges such as logistics costs and workforce expertise underscore the market's evolution. States like California",
    "url": "https://finnhub.io/api/news?id=eb8a02abf93aa446f2a038731d8e04b6c8187eeb84d1066ec4654dd43b6166e4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761653100,
      "headline": "United State Cell and Gene Therapy Third-Party Logistics Market Analysis Report 2025-2033: Expansion Fueled by Rising R&D Expenditure, Regulatory Complexity, & Strong Demand from Major Biopharma Hubs",
      "id": 137238016,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "COR",
      "source": "Yahoo",
      "summary": "The U.S. Cell and Gene Therapy Third-Party Logistics (3PL) Market is anticipated to surge from US$ 2.61 billion in 2024 to US$ 5.88 billion by 2033, maintaining a CAGR of 9.46% from 2025 to 2033. Key growth drivers include increased therapy adoption, specialized logistics needs, and expanding biopharmaceutical collaborations. Regulatory demands, cold chain technology adoption, and challenges such as logistics costs and workforce expertise underscore the market's evolution. States like California",
      "url": "https://finnhub.io/api/news?id=eb8a02abf93aa446f2a038731d8e04b6c8187eeb84d1066ec4654dd43b6166e4"
    }
  }
]